Verlene Henry
Impact in
- Genetics top 2%
- Glioma Diagnosis and Treatment
- Immunology top 5%
- Immune cells in cancer
- Immunotherapy and Immune Responses
Papers in
-
- PI3K/AKT/mTOR signaling in cancer 1
- Angiogenesis and VEGF in Cancer 1
- Ubiquitin and proteasome pathways 1
- Protein Degradation and Inhibitors 1
- Oncology 4
- CAR-T cell therapy research 3
- Co-authors
- Yuji Piao (8 shared papers)Ji Liang (3 shared papers)Lindsay Holmes (3 shared papers)John F. de Groot (3 shared papers)Ningyi Tiao (6 shared papers)Gregory N. Fuller (2 shared papers)Erik P. Sulman (4 shared papers)Amy B. Heimberger (3 shared papers)
- Journals
- Neuro-Oncology (4 papers)Clinical Cancer Research (3 papers)Oncotarget (3 papers)Cancer Research (2 papers)Journal of Neuro-Oncology (1 paper)
- Partner nations
- United StatesSpain
In The Last Decade
Verlene Henry
17 papers receiving 1.2k citations
Peers
Comparison fields: 5 of 70
- Genetics 400
- Immunology 415
- Cancer Research 242
- Oncology 428
- Neurology 96
Countries citing papers authored by Verlene Henry
This map shows the geographic impact of Verlene Henry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Verlene Henry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Verlene Henry more than expected).
Fields of papers citing papers by Verlene Henry
This network shows the impact of papers produced by Verlene Henry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Verlene Henry. The network helps show where Verlene Henry may publish in the future.
Co-authors
The 25 scholars most cited alongside Verlene Henry, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 253 | |
| 2 | 2013 | 238 | |
| 3 | 2010 | 231 | |
| 4 | 2013 | 160 | |
| 5 | 2016 | 53 | |
| 6 | 2020 | 51 | |
| 7 | 2019 | 43 | |
| 8 | 2016 | 33 | |
| 9 | 2019 | 32 | |
| 10 | 2005 | 29 | |
| 11 | 2017 | 29 | |
| 12 | 2015 | 28 | |
| 13 | 2019 | 25 | |
| 14 | 2018 | 16 | |
| 15 | Depletion of CLK2 sensitizes glioma stem-like cells to PI3K/mTOR and FGFR inhibitors. | 2020 | 8 |
| 16 | 2018 | 2 | |
| 17 | 2017 | 1 |
About Verlene Henry
Verlene Henry is a scholar working on Molecular Biology, Oncology, Immunology, Genetics and Genetics, having authored 17 papers that have together received 1.2k indexed citations. Recurring topics across this work include CAR-T cell therapy research (3 papers), Virus-based gene therapy research (2 papers), PI3K/AKT/mTOR signaling in cancer (1 paper), Angiogenesis and VEGF in Cancer (1 paper), Ubiquitin and proteasome pathways (1 paper), Bioactive Compounds and Antitumor Agents (1 paper), Immunotherapy and Immune Responses (1 paper) and Protein Degradation and Inhibitors (1 paper). The work is most often cited by research in Genetics (400 citations), Immunology (415 citations), Cancer Research (242 citations), Oncology (428 citations) and Neurology (96 citations). Verlene Henry has collaborated with scholars based in United States and Spain. Frequent co-authors include Yuji Piao, Ji Liang, Lindsay Holmes, John F. de Groot, Ningyi Tiao, Gregory N. Fuller, Erik P. Sulman, Amy B. Heimberger, Frederick F. Lang and Ganesh Rao. Their work appears in journals such as Neuro-Oncology, Clinical Cancer Research, Oncotarget, Cancer Research and Journal of Neuro-Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.